A US clinical-stage biotech company developing oral small-molecule therapies for neuroscience, inflammation and immunology indications, now led by its wholly-owned lysophosphatidic acid receptor 1 antagonist PIPE-791 in idiopathic pulmonary fibrosis.
A US clinical-stage biotech company developing oral small-molecule therapies for neuroscience, inflammation and immunology indications, now led by its wholly-owned lysophosphatidic acid receptor 1 antagonist PIPE-791 in idiopathic pulmonary fibrosis.
